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Abstract
Background: Poor recruitment is the most common reason for premature discontinuation of randomised
controlled trials (RCTs). An RCT of medication versus psychological therapy for generalised anxiety disorder (GAD)
was discontinued prematurely by the UK National Institute of Health Research funders because of recruitment
failure. In order to inform future research studies, this article explores the reasons for poor recruitment and aspects
which could have been improved.
Methods: The trial recruited participants via psychological well-being practitioners (PWPs) employed within local
Improving Assess to Psychological Therapies (IAPT) services at four sites in England. For this study, we initially
examined the recruitment data to identify reasons why potential participants were reluctant to participate in the
trial. We then investigated reasons the PWPs did not identify more potential participants. Finally, we performed
retrospective analyses of a computerised clinical records system used by the IAPT services in this study. These
analyses aimed to establish the number of potential participants who had not been approached about the trial as
well as whether there were additional factors affecting the numbers of people who might be eligible to take part.
Data were obtained for all patients assessed during the period from the date on which recruitment commenced
until the closure of the trial.
Results: Three quarters of those patients identified as possibly suitable for the trial declined to take part; the great
majority did so because they did not want to be randomly assigned to receive medication. Our retrospective
database analyses showed that only around 12% of potentially eligible patients for the trial were identified by the
PWPs at the pilot sites. The results also indicated that only 5% of those noted at entry to the IAPT services to have
a score of at least 10 on the GAD-7 questionnaire (a self-completed questionnaire with high sensitivity and
specificity for GAD) would have been eligible for the trial.
Conclusions: Our findings suggest that poor recruitment to RCTs can be significantly affected by participants’
treatment preferences and by factors influencing the recruiting clinicians. It may also be important not to include
too many restrictions on inclusion criteria for pragmatic trials aiming for generalisable results.
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Background
Randomised controlled trials (RCTs) are considered the
‘gold standard’ for evaluating the effectiveness of inter-
ventions [1]. However, conducting high-quality RCTs
may prove to be challenging because of unexpected
events that occur ‘en route’, leading to premature discon-
tinuation in an estimated 25% of RCTs conducted in
Europe, Canada and Australia [2–4].
Trials may be stopped prematurely for a variety of
factors, including unexpected harmful events [5] and
greater-than-expected benefits of the intervention mani-
festing early in the trial [6]. New findings answering the
primary research question or raising concerns about the
safety of the intervention may also arise [7]. Although
these factors play a role in the premature discontinu-
ation of RCTs, the literature suggests that the main
reason for terminating a study early is the slow and
inadequate recruitment of participants [3, 8, 9]. This,
along with evidence indicating that recruitment is
adequate and timely in only 50% of RCTs worldwide
[10], renders recruitment a key issue. In the UK, several
studies have reported similar results in trials funded by
two of the UK’s largest funding agencies: the UK
Medical Research Council and the National Institute of
Health Research (NIHR) Health Technology Assessment
(HTA) Programme [9, 11, 12].
An NIHR HTA–funded trial of the anti-depressant ser-
traline versus cognitive behavioural therapy (CBT) for
generalised anxiety (ToSCA) had to be discontinued pre-
maturely because of a failure to recruit. Generalised anx-
iety disorder (GAD) is common, has distressing symptoms
and often is associated with poor general functioning, sub-
stance misuse and financial difficulties [13, 14]. The 2011
UK National Institute for Health and Clinical Excellence
(NICE) guidelines recommend low-intensity psychological
therapies as the best initial treatment, but it is uncertain
whether pharmacological or psychological therapy pro-
vides the most effective longer-term treatment for those
not responding to low-intensity therapies [15]. The NIHR
HTA commissioned and funded ToSCA, a UK, multi-site,
phase IV RCT aiming to answer this question by assessing
the clinical effectiveness at 12months of treatment with
the anti-depressant drug sertraline compared with
high-intensity CBT in participants with established GAD,
who had failed to respond to a low-intensity psychological
intervention. The study outcomes included measures of
the effects of anxiety, participant satisfaction and health
economic data.
The study set-up started in August 2014, and participant
recruitment was anticipated to commence in February
2015. However, participant recruitment was delayed until
July 2015 because of several research governance issues, at
both a national and a local level, which required consult-
ation with both the lead Clinical Research Network and
the Health Research Authority as well as local research
and development (R&D) offices for the pilot sites. This
was due to a query as to whether participating general
practitioner (GP) practices should be registered as individ-
ual research sites, which would have been administratively
burdensome given that most of the planned 360 trial par-
ticipants were likely to be registered at different practices.
This was addressed with a generic site-specific informa-
tion form developed by working together with the lead
Clinical Research Network and the Health Research
Authority, and study-wide R&D approval was received 3
months after initial submission of the full set of docu-
ments, although it took a further 2 months to receive local
assurances for all of the pilot sites. These delays were very
time-consuming and meant that we were not in a position
to start work on recruiting participants as planned and
initially discussed with the pilot sites, but ultimately they
were not the main reason for the failure to recruit as
described in the article. The trial aimed to recruit partici-
pants via local Improving Access to Psychological Therap-
ies (IAPT) services [16] that served as participating sites.
The initial internal pilot phase of the study was planned to
run for 12months and involve four pilot IAPT sites.
Unfortunately, however, at 6 months into the internal pilot
in January 2016, despite varied attempts to improve par-
ticipant recruitment, only five patients had been randomly
assigned across all of the pilot sites against a target of 40
by this stage. After a monitoring meeting between the
study team and the funders, the NIHR HTA decided to
discontinue the study and asked the trial team to stop
recruiting new participants and to make plans to close
down the trial.
Premature discontinuation of RCTs is costly in terms
of resources and a failure to answer the underlying
research question and is potentially frustrating for the
investigators [9, 10, 17] and for the research ethics
committees and regulatory agencies that need to devote
a considerable amount of time and effort to review
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protocols [10, 18, 19]. It also raises ethical considerations
for patients who have consented to be involved. There-
fore, it is very important to evaluate and learn pertinent
lessons from previous trials where this has happened.
In light of our experience with the ToSCA trial, we
went back to the initial trial design to assess at what
points our assumptions about potential recruitment
strategies were unsuccessful, and what might have been
improved upon or changed in terms of the trial design,
in order to give a better chance of a successful outcome.
Making this information available to the scientific com-
munity may help others to learn from our experience.
Methods
Participants’ recruitment
Because one of the inclusion criteria to the trial stipulated
by the HTA was the failure of patients with diagnosed
GAD to have improved with low-intensity psychological
interventions delivered by IAPT, the decision was made to
recruit trial participants from IAPT sites. Thus, the initial
identification of potential participants was carried out by
psychological well-being practitioners (PWPs) at the four
pilot sites: (i) Camden and Islington (this included the local
IAPT service in Kingston as managed by the same National
Health Service (NHS) Trust), (ii) Greenwich, (iii) Bristol
and (iv) Coventry and Warwick. They were responsible for
administering the low-intensity psychological interventions
(step 2), which the NICE guidelines indicate should be of-
fered to GAD patients who have not responded to simple
education about GAD and active monitoring (step 1). The
PWPs would then review patients to see whether they had
improved clinically with this intervention and, if not, were
in a position to discuss referral to a more intensive psycho-
logical intervention (step 3). The trial question was framed
around step 3 in the NICE-recommended patient pathway
(Fig. 1); it was at this point that the PWPs were asked to
raise the topic of the trial with any patients still scoring at
least 10 on the GAD-7, a seven-item self-completion ques-
tionnaire with very good sensitivity (89%) and specificity
(82%) for GAD, which is one of the core measures regu-
larly administered by IAPT services [20]. Some patients
who are more severely affected and who have marked
functional impairment may bypass step 2 and go directly
to step 3. Under this trial protocol, they would not have
been approached about taking part in the study, although
clinically this might have been appropriate in terms of the
interventions being offered within the trial.
Interested patients were provided with a full patient
information sheet; with their written consent, a full
assessment of their eligibility for the trial was conducted
by a member of the research team. Eligible adult partici-
pants had to have a primary diagnosis of GAD as
diagnosed on the Mini International Neuropsychiatric
Interview (MINI) and a positive score of at least 10 on
the GAD-7 questionnaire and had to fulfil the other
inclusion criteria for the trial [21]. Exclusion criteria in-
cluded having a comorbid psychotic disorder or bipolar
disorder receiving treatment with anti-depressants in the
past 8 weeks, having had any high-intensity psycho-
logical therapy within the past 6 months, and having
current major depression (identified on the MINI) or
any comorbid anxiety disorder (also confirmed using the
Fig. 1 UK National Institute for Health and Clinical Excellence (NICE) stepped care model for generalised anxiety disorder. Abbreviations: GP
general practitioner, iapt Improving Access to Psychological Therapies, SSRI selective serotonin reuptake inhibitor
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MINI) of more perceived severity than their GAD and
any contra-indications for treatment with sertraline
([21], page 8]). Any potential participants expressing
thoughts of self-harm at the baseline interview would be
screened for significant suicidal ideation by the re-
searcher using an established proforma and referred to
their GP or for acute psychiatric assessment if indicated.
After giving informed consent and fulfilling all of the eli-
gibility criteria, participants were randomly assigned to
either sertraline or CBT via a web-based independent
randomisation service.
Anticipated participant recruitment rates
Patients seen by the PWPs at the low-intensity interven-
tion stage do not all have a definitive psychological diag-
nosis made, so it is difficult to be sure what number
would have definite GAD as distinct from other anxiety
disorders or major depression which are often comorbid
with GAD. However, they would all have recorded out-
comes on the GAD-7 questionnaire, on which a score of
at least 10 is suggestive of GAD, as described above. We
therefore asked the PWPs to broach assessment for
inclusion in the trial with any of their patients who had
a GAD-7 score of at least 10 at the end of their
low-intensity treatment; the rationale was that a defini-
tive diagnosis would be made when people were being
formally assessed for inclusion. Considering retrospect-
ive figures from the local IAPT service in Camden and
Islington, which had a combined population of 426,000
in 2011–12, we aimed to recruit two participants per
month from each of the four pilot sites during the
internal pilot with a slower recruitment phase for the
first 3 months whilst we were refining our procedures
[21]. The overall target for the internal pilot was 90 par-
ticipants at 12 months and the aim was for 40 at 6
months. It was clear from an early stage in the trial that
recruitment was not going as scheduled and a range of
interventions were implemented to try to improve this.
Interventions aiming to improve participant recruitment
Given that successful recruitment to the trial was
dependent on recruitment by the IAPT PWPs, we
employed a number of interventions aiming to improve
recruitment by the PWPs as soon as we became aware
of the difficulties with participant recruitment. These
included the following:
 Materials produced to help the PWPs keep the
study and recruitment in mind. These included
reminders of the study eligibility criteria and a crib
sheet of points to discuss with possible participants,
including a proposed approach to the presentation
of the trial and planned interventions as well as
suggested responses to queries which might have
been raised.
 Funding of lead PWPs to facilitate recruitment.
These PWPs were employed by their local IAPT
services, where they worked clinically as well as
having dedicated, locally funded sessions to facilitate
recruitment.
 Regular reminders and meetings with the PWPs
about the trial. Members of the research team
attended some of these meetings to answer any
queries which the PWPs might have about
participant recruitment, and several sites used their
PWP case management and supervision sessions to
highlight patients who might be suitable for the trial
at the end of their low-intensity intervention.
 Database searches to identify possible cases. The
IAPTUS database, a computerised clinical records
system used by all of the IAPT services in this study
(IAPTUS; adult version, Mayden) [22], was used to
develop an algorithm to identify patients coming to
the end of their low-intensity treatment. These
patients might have been suitable to approach for
the trial if their most recent GAD score was at least
10 and they were known not to be on psychotropic
medication. This information was then circulated to
the PWPs seeing the identified patients.
Retrospective analysis of IAPT patient data
Following on from this work during the trial, which did not
significantly improve the participant recruitment rates, we
performed some retrospective analyses of the IAPTUS
database after the study had been terminated, to try to es-
tablish whether potential participants who could have been
approached about the trial had been missed or whether
there were other factors affecting the numbers of people
who might be eligible to take part. Data were obtained for
all patients assessed during the period from the date that
participant recruitment commenced on 1 July 2015 until
closure of the ToSCA trial on 8 February 2016 and they
were then tracked to completed treatment and discharge.
Data were extracted from the Patient Management Soft-
ware for Psychological Therapies [22] for the IAPT pilot
sites in Camden and Islington (including the service located
in Kingston) and Bristol. Owing to staff shortages combined
with the complexity of the data extraction procedure, data
were not extracted for the Greenwich and Coventry &
Warwick IAPT sites. Filters were then applied to the data
to obtain information relevant to the ToSCA trial. (Further
details are available from the study team on request.)
Results
Actual recruitment to the ToSCA trial
During the recruitment period, 60 potential participants
were identified by the PWPs as potentially suitable to
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take part in the trial across the four IAPT pilot sites. In
all of these cases, the PWPs discussed the study with the
patient and then informed the research team of the re-
sults of their discussions. Out of the 60 cases, 53 were
excluded from further assessment; the majority (n = 45)
were excluded because the patients declined to partici-
pate (see Consort diagram Fig. 2). The remaining seven
underwent baseline assessments, at which two were
deemed ineligible for the study (one because GAD was
not the psychological problem causing them the most
concern and one because they were identified as having
comorbid major depression) and five were randomly
assigned to either sertraline (n = 3) or CBT (n = 2). The
main reason for patients not wanting to take part in the
trial was that they were reluctant to consider being ran-
domly assigned to the medication arm of the trial or
they had a definite preference for treatment with CBT
or both (33/45).
Reasons given by PWPs for not identifying potentially
eligible patients
It was clear that time and caseload pressures were sig-
nificant factors for the PWPs, as was the fact that they
perceived their clinical work as their priority; given that
they were working in a psychological therapy service,
they might also have had a subconscious bias towards
considering that a psychological treatment for GAD was
preferable to medication.
In the PWP meetings attended by the research team to
discuss and answer queries about recruitment, the PWPs
reported on patients who were potentially eligible for the
study but whom they had not identified to the research
team. On a few occasions, they had forgotten to discuss
the study with the patient; they were sometimes able to
rectify this by contacting them and having that discussion.
However, the most common issue reported was that the
PWP or their supervisor considered that another difficulty
described by the patient, such as another anxiety disorder
or depression or social difficulties such as severe debt, was
the more clinically appropriate problem to treat than any
possible or probable GAD. In such cases, the PWP did
not consider the patient relevant for the study and so did
not discuss it with the patient or identify them to the re-
search team. Although the research team clarified that the
research baseline assessment would determine whether
the patient met GAD diagnostic criteria and whether their
GAD or major depression or a comorbid anxiety problem
was the most clinically appropriate and salient problem to
the patient to treat, the view expressed by supervisors at
the meetings was that it would not be in the best clinical
interest of patients to suggest the study to them when the
clinical opinion was that treatment targeting GAD would
probably not be appropriate.
Fig. 2 Consort diagram. Abbreviations: CBT cognitive behavioural therapy, GP general practitioner, PWP psychological well-being practitioner
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Retrospective analysis of IAPT data to identify potential
participants
In order to identify the number of potentially eligible
and approachable patients for the ToSCA trial, the cri-
teria shown in the flow chart (Fig. 3) were used. During
the study period from the date participant recruitment
commenced on 1 July 2015 until closure of the ToSCA
trial on 8 February 2016, 11,091 patients with an initial
GAD-7 result recorded were assessed by the IAPT ser-
vices across the Camden and Islington (including the
IAPT service located in Kingston) and Bristol pilot sites.
At this initial clinical assessment, 7602 patients had a
score of at least 10 on the GAD-7 questionnaire and
2120 (28%) of these patients had subsequently received
three or more low-intensity treatment sessions.
However, 885 out of the 2120 patients who had received
three or more low-intensity treatment sessions were re-
corded in IAPTUS as currently taking anti-depressant
medication, and in a further 55 cases, it was not known
whether this was the case or not, meaning that 940
patients were not eligible for the study for this reason. Of
the remaining 1180 patients who had received at least
three low-intensity sessions and were known not to be
taking anti-depressants, 605 were recorded as having
recovered and thus were not eligible for the trial, leaving
575 potentially eligible patients at this stage.
A further filter was applied to remove patients who had
dropped out of low-intensity treatment (n = 183), were
considered unsuitable for a further intervention (n = 7) or
had indicated to the PWP that they did not want any
further intervention (n = 19). This meant that only 366
patients (5% of the original number with an initial GAD-7
score of at least 10) across these two pilot sites would have
been potentially approachable for the trial as having a
GAD score of at least 10, not being on anti-depressants
and having not responded to low-intensity therapy.
Fig. 3 Flow chart showing total database figures for two pilot sites. Abbreviations: GAD-7 Generalised Anxiety Disorder 7, IAPT Improving Access to
Psychological Therapies
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Although this is considerably more patients than the 44
identified and screened by the PWPs at these two pilot
sites during the study period (only 16 of the overall study
total of 60 patients were identified and screened at the
Greenwich and Coventry and Warwick sites), it is still
only around 5% of the 7602 patients with a GAD-7 score
of at least 10 at their baseline assessment.
Discussion
The overall aim of this study was to identify reasons for
the poor recruitment to the ToSCA trial which had re-
sulted in its premature closure. Our retrospective data-
base work indicates that only around 12% of potentially
eligible patients for the trial were identified by the PWPs
at the pilot sites, but the database results also indicate
that only a small percentage (5%) of people assessed by
the IAPT service with a GAD-7 score of at least 10 and
thus possible GAD would have been eligible. In addition,
of those patients who were identified by the PWPs in
our study as possibly suitable for the trial, three quarters
(45/60) declined to take part; the great majority did so
because they did not want to be randomly assigned to
receive medication.
These findings are in line with the results of a Cochrane
review suggesting that poor recruitment to RCTs can be
significantly affected by factors influencing the recruiting
clinicians [23]. A major problem within the trial appears
to have been a low rate of identification of potential par-
ticipants by the PWPs. We investigated this during the
pilot phase and identified several contributing factors, in-
cluding the fact that the PWPs were clinically stretched
and most did not see the research project as a priority for
their time. Fletcher et al. [17] suggested that funding-pro-
tected research time and having extra staff support [23]
could improve recruitment. We managed to secure some
additional funding for the lead PWPs (one lead PWP per
pilot site) but unfortunately this did not have a significant
positive impact on recruitment. Another factor contribut-
ing to the low identification rate of potential participants
by the PWPs may have been that they are trained to de-
liver a low-intensity CBT intervention which may have
given them a bias, whether conscious or not, towards psy-
chological therapy. There is a potential tension between
clinical and research roles when asking clinicians to re-
cruit to research studies [17]. As the recruiting clinicians
often also have a gatekeeper role, they may approach only
patients whom they personally deem suitable to take part
and not all potentially eligible patients for a trial. Add-
itionally, there is evidence for an association between cli-
nicians’ orientation towards research and successful
recruitment of patients for clinical trials [23]. Training
programmes for clinicians recruiting for RCTs consisting
specifically of workshops over one or two consecutive days
covering trial-specific and generic research issues may also
contribute to enhanced recruitment [24].
Although we thought we had discussed the trial in
some detail with the IAPT services involved, it might
have been helpful to have discussed the implications of
study eligibility criteria more thoroughly in advance with
key stakeholders, such as senior clinicians/managers, in
order to anticipate potential differences in perspective
between clinicians and researchers about the appropri-
ateness for referral to the trial. An alternative might have
been to involve members of the research team more dir-
ectly in participant recruitment (e.g., by placing them
within the PWP clinics) but this would have had signifi-
cant resource implications and was not encouraged by
the IAPT services involved.
As only 5% of the 7602 patients passing through the
IAPT pilot sites were identified in the database search as
potentially eligible for recruitment to the trial, this
would have made the whole process very tight. Further-
more, a significant number of the 5% might have not ful-
filled all of the study eligibility criteria in terms of not
having major depression or having another more signifi-
cant anxiety disorder, further reducing the population of
GAD patients who met eligibility criteria for the study.
For example, if one extrapolates from our pilot study, it
is possible that three quarters of the 366 deemed poten-
tially eligible may have not wanted to take part, reducing
the sample to merely 91 people.
The likelihood that many of the 5% would have an-
other disorder may correlate with the concerns held by
the IAPT supervisors about what is the most significant
disorder affecting each individual patient. Most GAD is
known to be comorbid with other axis 1 disorders [15].
The study criteria would have excluded at baseline as-
sessment all those with comorbid depression and pa-
tients considering a comorbid anxiety disorder more
significant than their GAD, but it would have been of
benefit to get these more accurate figures, not only for
recruitment to this trial but also in terms of assessing
the relevance of the trial eligibility criteria for the overall
service provision for GAD. Shortage of eligible patients
(i.e., identification of fewer eligible patients than origin-
ally anticipated) has previously been reported as a major
obstacle to recruitment in relation to the design and
conduct of RCTs [25–27].
In addition, the PWPs stated that their patients were
often reluctant to consider a design in which they might
be randomly assigned to medication rather than a psy-
chological intervention. Patients’ treatment preferences
have been widely reported as key barriers to recruitment
[28–31], and a meta-analysis of patient views about
receiving psychological or pharmacological treatment for
a range of psychiatric disorders indicated a significant
preference for psychological treatment [32]. This patient
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view might have been amplified by the fact that they
were already receiving treatment within a psychological
therapy service.
Prior experience of treatment has been listed by Stig-
gelbout and de Haes [33] as a factor shaping patients’
treatment preferences. It has also been demonstrated that
the way in which the information about the interventions
is presented or ‘framed’ may play a role in shaping pa-
tients’ treatment preferences [34, 35]. We attempted to
address this factor by suggesting appropriate approaches
for the presentation of the trial and the planned interven-
tions as well as suitable responses which the PWPs might
give to patient concerns about receiving treatment with
anti-depressants, but we had little success. The fact that
the medication (i.e., the anti-depressant drug sertraline)
was available outside of the trial and that patients were
able to get a prescription for it from their GP if they
wished might have also played a role in patients’ reluc-
tance to take part in the trial. It would have been very
helpful to conduct semi-structured qualitative interviews
with both patients and PWPs to further explore these is-
sues around poor recruitment, but unfortunately there
was no funding available to do this.
Conclusions/Future research
An alternative research design may be appropriate to inves-
tigate the main clinical question which remains to be an-
swered, namely whether high-intensity CBT or medication
has a better longer-term impact for people with clinically
significant GAD. This might be carried out by recruiting
potential participants from primary care rather than subse-
quent to referral for a low-intensity treatment in an IAPT
setting, as primary care is where initial discussions about
whether patients would prefer a pharmacological or psy-
chological approach usually take place and they may be
more prepared to accept randomisation to either at this
stage. This might mean circumventing the low-intensity
treatment indicated at step 2 in the NICE guidelines, and
our database work indicated that quite a large number of
people with a GAD-7 score of at least 10 improved with
three or more sessions of low-intensity therapy (Fig. 3), but
an alternative design might be for those in the psychological
therapy arm to be initially offered low-intensity therapy and
to proceed to high-intensity therapy only if they did not im-
prove. In addition, it would probably be clinically appropri-
ate to ask people being stepped straight up to a step 3
psychological intervention whether they would be inter-
ested in taking part in the trial, which was not the case with
the design used in the ToSCA trial. Each research design
has its pros and cons, but a lesson from this trial might be
not to propose or commission a randomised trial with too
many restrictions which may affect recruitment as this can
affect both participant recruitment and the generalisability
of any results.
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